

Mar Tintore

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2394135/mar-tintore-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

158
papers

9,276
citations

45
h-index

95
g-index

170
ext. papers

12,202
ext. citations

7.1
avg, IF

5.84
L-index

#	Paper	IF	Citations
158	Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre.. <i>Journal of Neurology</i> , 2022 , 269, 1764	5.5	0
157	Prognosis of a second clinical event from baseline MRI in patients with a CIS: a multicenter study using a machine learning approach.. <i>Neuroradiology</i> , 2022 , 1	3.2	
156	Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis.. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022 , 9,	9.1	3
155	Neurotoxicity-associated sinus bradycardia after chimeric antigen receptor T-cell therapy.. <i>Hematological Oncology</i> , 2022 ,	1.3	0
154	Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585211061343	5	2
153	T1/T2-weighted ratio in multiple sclerosis: A longitudinal study with clinical associations.. <i>NeuroImage: Clinical</i> , 2022 , 34, 102967	5.3	0
152	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585211069068	5	1
151	Spinal cord grey matter atrophy in Multiple Sclerosis clinical practice. <i>Neuroscience Informatics</i> , 2022 , 100071		0
150	Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585221089540	5	1
149	Women's Health in Multiple Sclerosis: A Scoping Review.. <i>Frontiers in Neurology</i> , 2021 , 12, 812147	4.1	1
148	Optic Nerve Topography in Multiple Sclerosis Diagnosis: The Utility of Visual Evoked Potentials. <i>Neurology</i> , 2021 , 96, e482-e490	6.5	6
147	Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211053001	5	0
146	Assessment of automatic decision-support systems for detecting active T2 lesions in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211061339	5	0
145	Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis. <i>Journal of Neurology</i> , 2021 , 1	5.5	4
144	Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome: A MAGNIMS Study. <i>Neurology</i> , 2021 ,	6.5	4
143	Adding brain volume measures into response criteria in multiple sclerosis: the RB-4 score. <i>Neuroradiology</i> , 2021 , 63, 1031-1041	3.2	0
142	Menopause does not modify disability trajectories in a longitudinal cohort of women with clinically isolated syndrome and multiple sclerosis followed from disease onset. <i>European Journal of Neurology</i> , 2021 ,	6	3

141	Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211005339	5	18
140	Scoring the 10-year risk of ambulatory disability in multiple sclerosis: the RoAD score. <i>European Journal of Neurology</i> , 2021 , 28, 2533-2542	6	3
139	CSF chitinase 3-like 1 is associated with iron rims in patients with a first demyelinating event. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211010082	5	2
138	Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 49, 102717	4	4
137	The potential of serum neurofilament as biomarker for multiple sclerosis. <i>Brain</i> , 2021 , 144, 2954-2963	11.2	19
136	COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response. <i>European Journal of Neurology</i> , 2021 , 28, 3384-3395	6	60
135	Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. <i>Annals of Neurology</i> , 2021 , 89, 30-41	9.4	30
134	The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis centre of Catalonia. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 913-921	5	7
133	Multiple sclerosis is associated with higher comorbidity and health care resource use: A population-based, case-control study in a western Mediterranean region. <i>European Journal of Neurology</i> , 2021 , 28, 4124-4134	6	1
132	2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. <i>Lancet Neurology</i> , 2021 , 20, 653-670	24.1	44
131	Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome. <i>Neurology</i> , 2021 , 97, e1641-e1652	6.5	6
130	Myelin-oligodendrocyte glycoprotein antibody-associated disease. <i>Lancet Neurology</i> , 2021 , 20, 762-772	37	
129	Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patients. <i>Journal of Neurology</i> , 2021 , 1	5.5	3
128	The Multiple Sclerosis Data Alliance Catalogue: Enabling Web-Based Discovery of Metadata from Real-World Multiple Sclerosis Data Sources.. <i>International Journal of MS Care</i> , 2021 , 23, 261-268	2.3	2
127	DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity - Commentary.. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211049073	5	1
126	Ratio of T1-Weighted to T2-Weighted Signal Intensity as a Measure of Tissue Integrity: Comparison with Magnetization Transfer Ratio in Patients with Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2020 , 41, 461-463	4.4	6
125	Aggressive multiple sclerosis (2): Treatment. <i>Multiple Sclerosis Journal</i> , 2020 , 1352458520924595	5	6
124	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. <i>Multiple Sclerosis Journal</i> , 2020 , 1352458520925369	5	14

123	Radiologically Isolated Syndrome: 10-Year Risk Estimate of a Clinical Event. <i>Annals of Neurology</i> , 2020 , 88, 407-417	9.4	35
122	Keeping standards of multiple sclerosis care through the COVID-19 pandemic. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1153-1156	5	13
121	MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. <i>Nature Reviews Neurology</i> , 2020 , 16, 171-182	15	68
120	Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. <i>Lancet Neurology</i> , 2020 , 19, 234-246	24.1	86
119	A validation study of manual atrophy measures in patients with Multiple Sclerosis. <i>Neuroradiology</i> , 2020 , 62, 955-964	3.2	4
118	Value of 3T Susceptibility-Weighted Imaging in the Diagnosis of Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2020 , 41, 1001-1008	4.4	30
117	Author response: Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis. <i>Neurology</i> , 2020 , 94, 456-457	6.5	
116	Prognostication and contemporary management of clinically isolated syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 ,	5.5	1
115	Sex effects across the lifespan in women with multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2020 , 13, 1756286420936166	6.6	19
114	Harnessing Real-World Data to Inform Decision-Making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS). <i>Frontiers in Neurology</i> , 2020 , 11, 632	4.1	23
113	Multiple sclerosis management during the COVID-19 pandemic. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1163-1171	34	
112	The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history. <i>Brain</i> , 2020 , 143, 2637-2652	11.2	22
111	Menopause and multiple sclerosis: Influence on prognosis and role of disease-modifying drugs and hormonal replacement therapy. <i>Multiple Sclerosis Journal</i> , 2020 , 1352458520952022	5	2
110	The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1658-1669	5	18
109	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Lancet Neurology</i> , 2019 , 18, 185-197	24.1	74
108	Oligoclonal bands do not represent dissemination in time in the 2017 revisions to the McDonald criteria. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1690-1691	5	5
107	Brain regional volume estimations with NeuroQuant and FIRST: a study in patients with a clinically isolated syndrome. <i>Neuroradiology</i> , 2019 , 61, 667-674	3.2	6
106	Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis. <i>Neurology</i> , 2019 , 92, e1507-e1516	6.5	31

105	Oligoclonal bands increase the specificity of MRI criteria to predict multiple sclerosis in children with radiologically isolated syndrome. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019 , 5, 2055217319836664	2	15
104	Head-to-head drug comparisons in multiple sclerosis: Urgent action needed. <i>Neurology</i> , 2019 , 93, 793-809	5	13
103	SVM recursive feature elimination analyses of structural brain MRI predicts near-term relapses in patients with clinically isolated syndromes suggestive of multiple sclerosis. <i>NeuroImage: Clinical</i> , 2019 , 24, 102011	5.3	23
102	An asymptomatic new lesion on MRI is a relapse and should be treated accordingly - Commentary. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1845-1847	5	2
101	Simultaneous CMV and infection following alemtuzumab treatment for multiple sclerosis. <i>Neurology</i> , 2019 , 92, 296-298	6.5	13
100	Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge. <i>Neurology</i> , 2019 , 92, 180-192	6.5	50
99	Frequency and relevance of IgM, and IgA antibodies against MOG in MOG-IgG-associated disease. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 28, 230-234	4	10
98	Treatment of multiple sclerosis - success from bench to bedside. <i>Nature Reviews Neurology</i> , 2019 , 15, 53-58	15	129
97	Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis: A case report. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1383-1385	5	5
96	The role of the cerebellum in multiple sclerosis-150 years after Charcot. <i>Neuroscience and Biobehavioral Reviews</i> , 2018 , 89, 85-98	9	31
95	The value of oligoclonal bands in the multiple sclerosis diagnostic criteria. <i>Brain</i> , 2018 , 141, 1075-1084	11.2	64
94	Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 214-221	5	43
93	The optic nerve should be included as one of the typical CNS regions for establishing dissemination in space when diagnosing MS - No. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 123-125	5	4
92	Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. <i>Brain</i> , 2018 , 141, 1085-1093	11.2	72
91	Cervical Cord Atrophy and Long-Term Disease Progression in Patients with Primary-Progressive Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2018 , 39, 399-404	4.4	16
90	Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study. <i>Lancet Neurology</i> , 2018 , 17, 133-142	24.1	66
89	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. <i>Lancet Neurology</i> , 2018 , 17, 162-173	24.1	2419
88	Brain atrophy 15 years after CIS: Baseline and follow-up clinico-radiological correlations. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 721-727	5	3

87	Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 301-312	5	55
86	Disability progression markers over 6-12 years in interferon-β-treated multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 322-330	5	45
85	Varicella-zoster meningovascularitis in a multiple sclerosis patient treated with natalizumab. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 358-360	5	12
84	SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1485-1498	5	14
83	Myasthenia gravis following alemtuzumab therapy for multiple sclerosis. <i>Neurology</i> , 2018 , 91, 622-624	6.5	6
82	Multiple sclerosis risk perception and acceptance for Brazilian patients. <i>Arquivos De Neuro-Psiquiatria</i> , 2018 , 76, 6-12	1.6	3
81	Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1843-1851	5	60
80	Treatment decisions in multiple sclerosis - insights from real-world observational studies. <i>Nature Reviews Neurology</i> , 2017 , 13, 105-118	15	126
79	Cumulative Dose of Macrocyclic Gadolinium-Based Contrast Agent Improves Detection of Enhancing Lesions in Patients with Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2017 , 38, 1486-1493	4.4	17
78	Radiologically isolated syndrome in children: Clinical and radiologic outcomes. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017 , 4, e395	9.1	24
77	Lesion topographies in multiple sclerosis diagnosis: A reappraisal. <i>Neurology</i> , 2017 , 89, 2351-2356	6.5	19
76	Grey matter atrophy is associated with disability increase in natalizumab-treated patients. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 556-566	5	17
75	The state of multiple sclerosis: current insight into the patient/health care provider relationship, treatment challenges, and satisfaction. <i>Patient Preference and Adherence</i> , 2017 , 11, 33-45	2.4	51
74	Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis. <i>Neurology</i> , 2016 , 87, 1368-74	6.5	37
73	Symptom tracking: from clinically isolated syndrome to advanced multiple sclerosis. <i>Neurodegenerative Disease Management</i> , 2016 , 6, 27-29	2.8	1
72	Multiple sclerosis: Dimethyl fumarate is coming of age. <i>Nature Reviews Neurology</i> , 2016 , 12, 436-7	15	4
71	Primary Progressive Multiple Sclerosis Evolving From Radiologically Isolated Syndrome. <i>Annals of Neurology</i> , 2016 , 79, 288-94	9.4	96
70	Improved Automatic Detection of New T2 Lesions in Multiple Sclerosis Using Deformation Fields. <i>American Journal of Neuroradiology</i> , 2016 , 37, 1816-1823	4.4	17

69	Assessing response to interferon-β in a multicenter dataset of patients with MS. <i>Neurology</i> , 2016 , 87, 134-40	6.5	74
68	Brain Volume Loss During the First Year of Interferon-Beta Treatment in Multiple Sclerosis: Baseline Inflammation and Regional Brain Volume Dynamics. <i>Journal of Neuroimaging</i> , 2016 , 26, 532-8	2.8	17
67	MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. <i>Lancet Neurology</i> , 2016 , 15, 292-303	24.1	486
66	Baseline clinical status as a predictor of methylprednisolone response in multiple sclerosis relapses. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 117-21	5	4
65	Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 1005-15	5.5	157
64	CSF examination still has value in the diagnosis of MS - Commentary. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 997-8	5	7
63	Neurofilament light chain level is a weak risk factor for the development of MS. <i>Neurology</i> , 2016 , 87, 1076-84	6.5	61
62	Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. <i>Nature Reviews Neurology</i> , 2015 , 11, 471-82	15	272
61	Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. <i>Brain</i> , 2015 , 138, 918-31	11.2	103
60	Defining high, medium and low impact prognostic factors for developing multiple sclerosis. <i>Brain</i> , 2015 , 138, 1863-74	11.2	302
59	Role of high mobility group box protein 1 (HMGB1) in peripheral blood from patients with multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2015 , 12, 48	10.1	22
58	Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients. <i>Nature Reviews Neurology</i> , 2015 , 11, 597-606	15	321
57	Peripheral blood non-MAIT CD8+CD161hi cells are decreased in relapsing-remitting multiple sclerosis patients treated with interferon beta. <i>Journal of Neuroimmunology</i> , 2015 , 288, 98-101	3.5	5
56	Should we systematically test patients with clinically isolated syndrome for auto-antibodies?. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1802-10	5	2
55	Predictive value of early brain atrophy on response in patients treated with interferon β <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015 , 2, e132	9.1	25
54	The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level-NO. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1240-2	5	3
53	Advances in the management of multiple sclerosis symptoms: pathophysiology and assessment of spasticity in multiple sclerosis. <i>Neurodegenerative Disease Management</i> , 2015 , 5, 15-7	2.8	2
52	Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab. <i>Annals of Neurology</i> , 2015 , 77, 447-57	9.4	43

51	Early predictors of multiple sclerosis after a typical clinically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1721-6	5	28
50	Multiple sclerosis in 2013: novel triggers, treatment targets and brain atrophy measures. <i>Nature Reviews Neurology</i> , 2014 , 10, 72-3	15	2
49	Comment on: Prevalence of brain magnetic resonance imaging meeting Barkhof and McDonald criteria for dissemination in space among headache patients <i>Multiple Sclerosis Journal</i> , 2014 , 20, 897-8	5	
48	Diagnostic value of brain chronic black holes on T1-weighted MR images in clinically isolated syndromes. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1471-7	5	22
47	Radiologically isolated syndrome: 5-year risk for an initial clinical event. <i>PLoS ONE</i> , 2014 , 9, e90509	3.7	190
46	Spinal cord MRI should always be performed in clinically isolated syndrome patients: No. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1686-7	5	6
45	N-acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis. <i>Journal of Neurology</i> , 2014 , 261, 2338-43	5.5	42
44	Validation of semaphorin 7A and ala-His-dipeptidase as biomarkers associated with the conversion from clinically isolated syndrome to multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2014 , 11, 181	10.1	22
43	Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1602-8	5	33
42	Therapeutic decisions in multiple sclerosis: moving beyond efficacy. <i>JAMA Neurology</i> , 2013 , 70, 1315-24	17.2	67
41	TNFRSF1A polymorphisms rs1800693 and rs4149584 in patients with multiple sclerosis. <i>Neurology</i> , 2013 , 80, 2010-6	6.5	19
40	Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1175-81	5	75
39	Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis. <i>Neurology</i> , 2013 , 80, 234-41	6.5	42
38	MRI criteria distinguishing seropositive NMO spectrum disorder from MS. <i>Neurology</i> , 2013 , 80, 1336	6.5	4
37	Sex and gender issues in multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2013 , 6, 237-48	48.6	254
36	Patients with neuromyelitis optica have a more severe disease than patients with relapsing-remitting multiple sclerosis, including higher risk of dying of a demyelinating disease. <i>Arquivos De Neuro-Psiquiatria</i> , 2013 , 71, 275-9	1.6	16
35	Serum biomarker gMS-Classifer2: predicting conversion to clinically definite multiple sclerosis. <i>PLoS ONE</i> , 2013 , 8, e59953	3.7	3
34	Risk acceptance in multiple sclerosis patients on natalizumab treatment. <i>PLoS ONE</i> , 2013 , 8, e82796	3.7	21

33	Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1193-6	5	19
32	Interferon β 1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up. <i>Archives of Neurology</i> , 2011 , 68, 1421-7		34
31	Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. <i>Brain</i> , 2010 , 133, 1082-93	11.2	197
30	Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. <i>Annals of Neurology</i> , 2010 , 67, 159-69	9.4	145
29	B cell expression of the inhibitory Fc gamma receptor is unchanged in early MS. <i>Journal of Neuroimmunology</i> , 2010 , 223, 135-7	3.5	5
28	A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis. <i>Archives of Neurology</i> , 2009 , 66, 587-92		96
27	New options for early treatment of multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2009 , 277 Suppl 1, S9-S11	3.2	13
26	Early onset multiple sclerosis: the role of gender. <i>Journal of the Neurological Sciences</i> , 2009 , 286, 31-4	3.2	24
25	New treatment measurements for treatment effects on relapses and progression. <i>Journal of the Neurological Sciences</i> , 2008 , 274, 80-3	3.2	5
24	A three-year, multi-parametric MRI study in patients at presentation with CIS. <i>Journal of Neurology</i> , 2008 , 255, 683-91	5.5	65
23	Rationale for early intervention with immunomodulatory treatments. <i>Journal of Neurology</i> , 2008 , 255 Suppl 1, 37-43	5.5	71
22	Will Rogers phenomenon in multiple sclerosis. <i>Annals of Neurology</i> , 2008 , 64, 428-33	9.4	66
21	MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. <i>Lancet Neurology</i> , 2007 , 6, 677-86	24.1	246
20	Interferon beta in secondary progressive multiple sclerosis : daily clinical practice. <i>Journal of Neurology</i> , 2007 , 254, 849-53	5.5	4
19	FXTAS in spanish patients with ataxia: support for female FMR1 premutation screening. <i>Molecular Neurobiology</i> , 2007 , 35, 324-8	6.2	12
18	Antimyelin antibodies with no progression to multiple sclerosis. <i>New England Journal of Medicine</i> , 2007 , 356, 426-8	59.2	45
17	MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. <i>Lancet Neurology</i> , 2006 , 5, 221-7	24.1	94
16	Altered maturation of circulating dendritic cells in primary progressive MS patients. <i>Journal of Neuroimmunology</i> , 2006 , 175, 183-91	3.5	32

15	Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. <i>Annals of Neurology</i> , 2006 , 59, 344-52	9.4	260
14	Fatigue in progressive multiple sclerosis is associated with low levels of dehydroepiandrosterone. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 487-94	5	51
13	Is optic neuritis more benign than other first attacks in multiple sclerosis?. <i>Annals of Neurology</i> , 2005 , 57, 210-5	9.4	93
12	Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre. <i>Journal of Neurology</i> , 2005 , 252, 795-800	5.5	52
11	Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2005 , 11, 306-9	5	167
10	Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2004 , 10, 413-6	5	22
9	Specificity of Barkhof criteria in predicting conversion to multiple sclerosis when applied to clinically isolated brainstem syndromes. <i>Archives of Neurology</i> , 2004 , 61, 222-4		27
8	Unconventional therapy in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2003 , 9, 320-2	5	15
7	Serial gadolinium-enhanced MRI in acute attack of multiple sclerosis treated with plasma exchange. <i>Journal of Neurology</i> , 2003 , 250, 243-4	5.5	4
6	The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-beta. <i>Journal of Neuroimmunology</i> , 2002 , 130, 194-201	3.5	68
5	Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials. <i>Annals of Neurology</i> , 2002 , 52, 400-6	9.4	89
4	Serial proton spectroscopy, magnetization transfer ratio and T 2 relaxation in pseudotumoral demyelinating lesions. <i>NMR in Biomedicine</i> , 2002 , 15, 284-92	4.4	11
3	Anticardiolipin antibodies are not a useful screening tool in a nonselected large group of patients with multiple sclerosis. <i>Annals of Neurology</i> , 2001 , 49, 408-411	9.4	30
2	Encephalopathy associated to autoimmune thyroid disease: a more appropriate term for an underestimated condition?. <i>Journal of the Neurological Sciences</i> , 2000 , 176, 65-9	3.2	98
1	Decreased cholecystokinin levels in cerebrospinal fluid of patients with adult chronic hydrocephalus syndrome. <i>Biological Psychiatry</i> , 1997 , 41, 804-9	7.9	16